1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Mitochondrial Disease Sequence Data Resource Consortium is a grant from NIH National Center for Advancing Translational Sciences (NCATS) that funds research infrastructure and clinical studies for rare mitochondrial diseases.
Administered through the North American Mitochondrial Disease Consortium (NAMDC), a member of the Rare Diseases Clinical Research Network, the program supports a network of 17 clinical centers focused on improving diagnosis and care, establishing natural history, supporting translational research, and investigating treatment for mitochondrial diseases caused by mutations in mitochondrial or nuclear DNA.
The consortium collaborates with the United Mitochondrial Disease Foundation and maintains a Clinical Registry and Biorepository. Eligible applicants include nonprofits, universities, state and local governments, and for-profit organizations.
Get alerted about grants like this
Get emailed when new opportunities from “NIH National Center for Advancing Translational Sciences (NCATS)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Grant Abstract: The North American Mitochondrial Disease Consortium (NAMDC) Grant Abstract: The North American Mitochondrial Disease Consortium (NAMDC) Grant Number: 5U54NS078059-12 Project Title: The North American Mitochondrial Disease Consortium (NAMDC) Abstract: A member of the Rare Diseases Clinical Research Network (RDCRN), the North American Mitochondrial Disease Consortium (NAMDC) has established a network of 17 clinical centers with a mission to improve the diagnosis and care, establish the natural history, support translational research, and investigate treatment of mitochondrial diseases.
Mitochondrial diseases are clinically and genetically heterogeneous disorders due to primary mutations in mitochondrial DNA (mtDNA) or nuclear DNA (nDNA). A consortium, acting in close collaboration with the key patient advocacy groups, including the United Mitochondrial Disease Foundation (UMDF), provides an optimal approach to these complex diseases.
With support of an NIH American Recovery and Reinvestment Act (ARRA) grant and 7 years of a U54 award, NAMDC has already generated produced a substantial research infrastructure: a powerful Clinical Registry, a Biorepository, a website for education and recruitment of patients, and mitochondrial disease Research Diagnostic Criteria, which provide an essential foundation for clinical projects and trials.
From this firm base, 19 productive patient-oriented projects have already sprouted, including: 4 natural history studies; 6 survey studies; and 9 pilot studies. The NAMDC training program has trained 5 clinician-investigators all of whom remain remarkably active in mitochondrial disease research.
This competitive renewal application proposes 5 major Research Projects and a new Career Enhancement program which will expand and reap further rewards from the labor invested to date in NAMDC.
The Research Projects are: 1) An expansion of the NAMDC Clinical Registry/Longitudinal Study and Biorepository with detailed analyses of at least 6 mitochondrial disorders and novel registry-based natural history studies of at least 3 diseases; 2) Application of next-generation sequencing to identify causative mutations in the ~40% of NAMDC Registry subjects whose diseases are genetically undefined in collaboration with the Mitochondrial disease SEQuence Data Resource (MSeqDR); 3) Development and utilization of new mitochondrial functional assays in tissues collected via minimally invasive techniques; 4) Extension of an advanced genetics study of pyruvate dehydrogenase deficiency with addition of an innovative biomarker newborn screening program and 5) A longitudinal expanded access study of deoxynucleoside therapy for thymidine kinase 2 (TK2) deficiency.
We propose to transform our NAMDC Fellowship into a Career Enhancement program; to initiate new pilot studies; and to transition NAMDC NIH financial support to a broader array of funding sources.
PUBLIC HEALTH RELEVANCE: As research on the mitochondrial role in human diseases progresses rapidly, the time is ripe for NAMDC, which provides infrastructure, diagnostic capabilities, and conducts rigorous natural history studies and clinical trials that are sorely needed for these generally devastating disorders.
Furthermore, because mitochondrial dysfunction is thought to contribute to pathogenesis of many common disorders, such as Parkinson disease and diabetes, studies of mitochondrial diseases have broad implications.
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, For-profit organizations. Confirm the full requirements in the official notice before applying.
Mitochondrial Disease Sequence Data Resource Consortium is funded by NIH National Center for Advancing Translational Sciences (NCATS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read articleNSF's Arctic Research Opportunities solicitation funds roughly 75 awards a year — up to $50 million — across six program areas from natural sciences to social sciences to the Arctic Observing Network. The July 15, 2026 target date is not a hard deadline, and understanding that distinction is the first strategic decision an Arctic researcher makes. Here is how the six doors differ and how to choose the right one.
Read article